[1]马媛媛,姬　萌,郭醉爽,等.昆仙胶囊治疗原发性IgA肾病疗效观察[J].新乡医学院学报,2021,38(10):961-965.[doi:10.7683/xxyxyxb.2021.10.013]
　MA Yuanyuan,JI Meng,GUO Zuishuang,et al.Effect of Kunxian capsule in the treatment of primary IgA nephropathy[J].Journal of Xinxiang Medical University,2021,38(10):961-965.[doi:10.7683/xxyxyxb.2021.10.013]
点击复制

昆仙胶囊治疗原发性IgA肾病疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年10
页码:
961-965
栏目:
临床研究
出版日期:
2021-10-05

文章信息/Info

Title:
Effect of Kunxian capsule in the treatment of primary IgA nephropathy
作者:
马媛媛1; 姬　萌1; 郭醉爽2; 马东红1; 许清玉1; 尚瑞华1; 侯玉龙1; 郭明好1
（1.新乡医学院第一附属医院肾脏病医院，河南　卫辉　453100；2.郑州大学第一附属医院肾内科，河南　郑州　450000）
Author(s):
MA Yuanyuan1; JI Meng1; GUO Zuishuang2; MA Donghong1; XU Qingyu1; SHANG Ruihua1; HOU Yulong1; GUO Minghao1
(1.The Nephrology Hospital,the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100,Henan Province,China;2.Department of Nephrology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,Henan Province,China)
关键词:
IgA肾病; 昆仙胶囊; 泼尼松; 尿蛋白定量
Keywords:
IgA nephropathy; Kunxian capsule; prednisone; proteinuria
分类号:
R692.3+1
DOI:
10.7683/xxyxyxb.2021.10.013
文献标志码:
A
摘要:
目的　探讨昆仙胶囊治疗原发性IgA肾病的疗效及安全性。方法　选择2018年10月至2020年4月新乡医学院第一附院医院诊治的63例原发性IgA肾病患者为研究对象，将患者按治疗方法分为泼尼松组（32例）和昆仙胶囊组（31例）。泼尼松组患者在常规治疗基础上给予醋酸泼尼松片0.5 mg·kg-1·d-1口服，连续治疗12周；昆仙胶囊组患者在常规治疗基础上给予昆仙胶囊口服，每次0.6 g，每日3次，连续治疗12周。比较治疗前、治疗4周、治疗12周时2组患者的24 h尿蛋白定量、血肌酐、血尿酸、血尿素、血清白蛋白及血红蛋白等指标变化，比较2组患者治疗期间不良反应发生情况。结果　治疗4周时，2组患者24 h尿蛋白显著低于治疗前（P＜0.05）；治疗12周时，2组患者24 h尿蛋白显著低于治疗前和治疗4周时（P＜0.05）；治疗前和治疗4周时，昆仙胶囊组与泼尼松组患者24 h尿蛋白比较差异无统计学意义（P>0.05）；治疗12周时，昆仙胶囊组患者24 h尿蛋白显著低于泼尼松组（P＜0.05）。2组患者治疗12周时的尿蛋白下降率显著高于治疗4周时（P＜0.05）；治疗4、12周时，昆仙胶囊组患者尿蛋白下降率显著高于泼尼松组（P＜0.05）。2组患者不同时间点组内、组间血肌酐水平比较差异均无统计学意义（P＞0.05）。2组患者治疗前血清白蛋白比较差异无统计学意义（P>0.05）；治疗4、12周时，泼尼松组患者血清白蛋白显著高于治疗前及昆仙胶囊组（P＜0.05）。昆仙胶囊组患者不同时间点血清白蛋白水平比较差异无统计学意义（P＞0.05）。2组患者血红蛋白、血尿酸及血尿素氮水平治疗前后组内、组间比较差异均无统计学意义（P＞0.05）。治疗12周后，昆仙胶囊组患者总缓解率为100.00%（31/31），泼尼松组患者总缓解率为78.13%（25/32）；昆仙胶囊组患者总缓解率显著高于泼尼松组（P＜0.05）。昆仙胶囊组患者不良反应发生率为3.23%（1/31），泼尼松组不良反应发生率为28.13%（9/32）；昆仙胶囊组患者不良反应发生率显著低于泼尼松组（P＜0.05）。结论　昆仙胶囊可显著降低原发性IgA肾病患者24 h尿蛋白水平，起效较泼尼松快，完全缓解率高，短期不良反应较少。
Abstract:
Objective　To investigate the efficacy and safety of Kunxian capsule in the treatment of primary IgA nephropathy.Methods　Sixty-three patients with primary IgA nephropathy admitted to the First Affiliated Hospital of Xinxiang Medical University from October 2018 to April 2020 were selected as research subjects,and they were divided into the prednisone group (n=32) and Kunxian capsule group (n=31) according treatment method.The patients in the prednisone group were given prednisone acetate tablets 0.5 mg · kg-1 · d-1 orally on the basis of routine treatment for 12 weeks;on the basis of routine treatment,the patients in the Kunxian capsule group were given Kunxian capsule orally,0.6 g each time,3 times per day for 12 weeks.The changes of 24-hour urinary protein,blood creatinine,blood uric acid,blood urea,serum albumin and hemoglobin of patients between the two groups before treatment,4 and 12 weeks of treatment were compared,and the incidence of adverse reactions of patients during treatment between the two groups was compared.Results　At 4 weeks of treatment, the 24-hours urinary protein of patients in the two groups was significantly lower than that before treatment (P<0.05); at 12 weeks of treatment, the 24-hours urinary protein of patients in the two groups was significantly lower than that before treatment and 4 weeks of treatment (P<0.05).There was no significant difference in 24-hours urinary protein of patients between the two groups before treatment and 4 weeks of treatment (P>0.05),the 24-hours urinary protein of patients in the Kunxian capsule group was significantly lower than that in the prednisone group at 12 weeks of treatment (P<0.05).The rate of urinary protein decrease of patients in the two groups at 12 weeks of treatment was significantly higher than that at 4 weeks of treatment (P<0.05),and the rate of urinary protein decrease of patients in the Kunxian capsule group was significantly higher than that in prednisone group at 4 and 12 weeks of treatment (P<0.05).There was no significant difference in serum creatinine levels between the two groups at different time points (P>0.05).There was no significant difference in serum albumin between the two groups before treatment (P＜0.05);at 4 and 12 weeks of treatment,the levels of serum albumin in the prednisone group were significantly higher than that before treatment and Kunxian capsule group (P＜0.05).There was no significant difference in serum albumin level in the Kunxian capsule group at different time points (P>0.05).There was no significant difference in the levels of serum creatinine,hemoglobin,serum uric acid and blood urea between the two groups at different time points (P>0.05).At 12 weeks of treatment,the total remission rate was 100.00%（31/31） in the Kunxian capsule group and 78.13% （25/32）in the prednisone group;the total remission rate in the Kunxian capsule group was significantly higher than that in the prednisone group (P＜0.05).The incidence of adverse reactions was 3.23%（1/31） in the Kunxian capsule group and 28.13% （9/32）in the prednisone group;the incidence of adverse reactions in the Kunxian capsule group was significantly lower than that in the prednisone group (P＜0.05).Conclusion　Kunxian capsule can significantly reduce the 24-hour urinary protein level in patients with IgA nephropathy,it has good short-term curative effect,quick effect and less adverse reactions compared with prednisone.

参考文献/References:

［1］　PENFOLD R S,PRENDECKI M,MCADOO S,et al.Primary IgA nephropathy:current challenges and future prospects［J］.Int J Nephrol Renovasc Dis,2018,11:137-148.
［2］　RAJASEKARAN A,JULIAN B A,RIZK D V.IgA nephropathy:an interesting autoimmune kidney disease［J］.Am J Med Sci,2021,361(2):176-194.
［3］　YEO S C,CHEUNG C K,BARRATT J.New insights into the pathogenesis of IgA nephropathy ［J］.Pediatr Nephrol,2018,33(5):763-777.
［4］　TANG Y,ZHANG Y,LI L,et al.Kunxian capsule for rheumatoid arthritis:inhibition of inflammatory network and reducing adverse reactions through drug matching［J］.Front Pharmacol,2020,11:485.
［5］　荆自伟,马真真,张丁丁,等.昆仙胶囊治疗蛋白尿的“成分-靶点-通路”研究［J］.中国医院药学杂志,2020,40(23):2396-2405.
［6］　刘枚,潘文友,孟德钎,等.昆仙胶囊联合糖皮质激素治疗狼疮性肾炎的临床研究［J］.中国中西医结合杂志,2020,40(8):919-922.
［7］　涂晓,杨梦蝶,李亚妤,等.昆仙胶囊与雷公藤多苷片治疗慢性肾脏病的疗效及安全性比较［J］.浙江中医药大学学报,2021,45(6):582-587,602.
［8］　姬萌,马媛媛,郭醉爽,等.昆仙胶囊与他克莫司治疗特发性膜性肾病疗效比较［J］.新乡医学院学报,2021,38(5):472-476.
［9］　TANG Y,HE H,SUN W,et al.Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score:a single center cohort study［J］.Mol Med Rep,2018,18(4):4103-4112.
［10］　LIU L J,YANG Y Z,SHI S F,et al.Effects of hydroxychloroquine on proteinuria in IgA nephropathy:a randomized controlled trial［J］.Am J Kidney Dis,2019,74(1):15-22.
［11］　张宁,易无庸.昆仙胶囊临床应用进展［J］.中医临床研究,2014,6(7):147-148.
［12］　HE L,PENG X,LIU G,et al.Anti-inflammatory effects of triptolide on IgA nephropathy in rats［J］.Immunopharmacol Immunotoxicol,2015,37(5):421-427.
［13］　WAN Q,LIU Z,YANG M,et al.Triptolide ameliorates fine particulate matter-induced podocytes injury via regulating NF-κB signaling pathway［J］.BMC Mol Cell Biol,2020,21(1):4.
［14］　曾佳丽,姜雪,余瑾,等.昆仙胶囊对IgA肾病大鼠的肾保护作用及系膜细胞增殖的影响［J］.中国现代医生,2019,57(31):38-42.
［15］　郑韵恒.昆仙胶囊治疗IgA肾病的临床疗效［D］.成都:成都医学院,2020.
［16］　严海英.昆仙胶囊治疗慢性肾小球肾炎的临床观察［D］.成都:成都中医药大学,2020.
［17］　RUSSO E,DROVANDI S,SALVIDIO G,et al.Increased serum uric acid levels are associated to renal arteriolopathy and predict poor outcome in IgA nephropathy［J］.Nutr Metab Cardiovasc Dis,2020,30(12):2343-2350.
［18］　ZHU B,LIU W H,YU D R,et al.The association of low hemoglobin levels with IgA nephropathy progression:a two-center cohort study of 1,828 cases［J］.Am J Nephrol,2020,51(8):624-634.
［19］　LU P,LI X,ZHU N,et al.Serum uric acid level is correlated with the clinical,pathological progression and prognosis of IgA nephropathy:an observational retrospective pilot-study［J］.Peer J,2020,8:e10130.
［20］　OH T R,SONG S H,CHOI H S,et al.The association between serum hemoglobin and renal prognosis of IgA nephropathy［J］.J Clin Med,2021,10(2):363.

相似文献/References:

[1]史洋洋,毕凌云,杨达胜.儿童紫癜性肾炎和IgA肾病的发病机制及病理分型研究进展[J].新乡医学院学报,2021,38(4):386.[doi:10.7683/xxyxyxb.2021.04.020]
[2]姬　萌,马媛媛,郭醉爽,等.昆仙胶囊与他克莫司治疗特发性膜性肾病疗效比较[J].新乡医学院学报,2021,38(5):472.[doi:10.7683/xxyxyxb.2021.05.016]
　JI Meng,MA Yuanyuan,GUO Zuishuang,et al.Comparison of the effects of Kunxian capsule and tacrolimus in the treatment of idiopathic membranous nephropathy[J].Journal of Xinxiang Medical University,2021,38(10):472.[doi:10.7683/xxyxyxb.2021.05.016]
[3]姚俊东,刘彬彬,王运昌,等.超微血流成像联合声脉冲辐射力弹性成像对IgA肾病的诊断价值[J].新乡医学院学报,2022,39(7):637.[doi:10.7683/xxyxyxb.2022.07.008]
　YAO Jundong,LIU Binbin,WANG Yunchang,et al.Value of superb microvascular imaging combined with aoustic radiation force impulse in diagnosis of IgA nephropathy[J].Journal of Xinxiang Medical University,2022,39(10):637.[doi:10.7683/xxyxyxb.2022.07.008]
[4]孙晓莉,郭永兵.小剂量泼尼松联合他克莫司治疗老年IgA肾病疗效观察[J].新乡医学院学报,2022,39(8):756.[doi:10.7683/xxyxyxb.2022.08.011]
　SUN Xiaoli,GUO Yongbing.Effect of low-dose prednisone combined with tacrolimus in the treatment of elderly patients with IgA nephropathy[J].Journal of Xinxiang Medical University,2022,39(10):756.[doi:10.7683/xxyxyxb.2022.08.011]
[5]李智恒,文青,蔡雪妮,等.IgA肾病治疗研究进展[J].新乡医学院学报,2023,40(3):295.[doi:10.7683/xxyxyxb.2023.03.019]
　LI Zhiheng,WEN Qing,CAI Xueni,et al.Research progress in the treatment of IgA nephropathy[J].Journal of Xinxiang Medical University,2023,40(10):295.[doi:10.7683/xxyxyxb.2023.03.019]

更新日期/Last Update: 2021-10-05